Inflammation in facioscapulohumeral muscular dystrophy

Completed

• Conditions: muscular dystrophy; 10028302

• Registration Number: NL-OMON43090
• Lead Sponsor: Radboud Universitair Medisch Centrum

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 10

Inclusion Criteria

-18-65 year old
-Genetically confirmed FSHD1

Exclusion Criteria

-Age <18 or > 65 years old
-Diabetes mellitus
-Chronic obstructive pulmonary disease
-Current malignancy
-Previous treatment with chemotherapy and/or radiation therapy
-Use of corticosteroids during more than two weeks in the past 5 years
-Use of statins in the past year

Study & Design

• Study Type: Observational non invasive
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>We expect to better understand if and which role inflammation plays in the<br /><br>disease pathogenesis by evaluating the following outcomes: percentage and<br /><br>features of PBMC, cytokine profiling and autoantibodies inquiry both in FSHD1<br /><br>patients and in healthy controls. Moreover, disease severity of FSHD patients<br /><br>will be assessed using a clinical severity score (Ricci-score).</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>not applicable </p><br>